Doximity is a free communication platform that helps connect medical professionals in 87 specialties to enable faster, smarter medical care. With Doximity, physicians can use their iPhone, iPad, Android device or computer to quickly connect with any U.S. physician to collaborate on patient treatment or identify appropriate experts for patient referrals.
KAI is a clinical-stage, biopharmaceutical company whose lead peptide product candidate, KAI-4169, is in development for the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). CKD-MBD is characterized by an elevation of parathyroid hormone also referred to as secondary hyperparathyroidism. KAI was acquired by Amgen in 2012.
Restoration Robotics is revolutionizing the field of hair transplantation by developing and commercializing ARTAS, a state-of-the-art image-guided system that improves the follicular unit extraction process. The office-based device is capable of rapidly harvesting and implanting individual hairs with minimal invasion, automating the tedious manual surgical technique now being performed by hair transplant surgeons.
Integrated Diagnostics develops large-scale, blood-based molecular diagnostics that leverage advances in proteomics and genomics to detect disease at its earliest stage. It leverages emerging technologies to develop diagnostic products used by physicians and patients to manage complex and serious diseases like cancer, diabetes and Alzheimer's. The company’s products work through blood tests that can monitor tens to hundreds of disease markers simultaneously. Integrated Diagnostics is headquartered in Seattle, Washington.
BioMimetic Therapeutics develops and commercializes clinically proven products to promote the healing of musculoskeletal injuries and diseases, including therapies for orthopedic and sports medicine applications. BioMimetic has become a leader in regenerative medicine by providing new treatment options for the repair of bone, cartilage, tendons and ligaments. BioMimetic was acquired by Wright Medical Group in 2013.
Cebix is a biopharmaceutical company focused on the development of chronic replacement therapy based on human proinsulin C-peptide for the treatment of diabetic complications, initially peripheral neuropathy in patients with type 1 diabetes.
Cardiac Dimensions develops novel interventional tools for the treatment of heart failure and the related conditions. Its Carillon Mitral Contour System is a groundbreaking, non-surgical device that uses a catheter-based approach to reshape the mitral valve and reduce mitral regurgitation.
Carbylan was founded in 2005 to develop and market medical devices and device/drug combination products based on novel, chemically-engineered polymer systems incorporating hyaluronic acid, a well known polysaccharide widely present in the human body. Its initial market focus is therapeutic medical devices and combination products to treat the pain associated with osteoarthritis. Carbylan biopolymers are biocompatible, non-immunogenic and, when combined with pharmaceutical agents, are designed to enable unique, controlled, local drug delivery with sustained therapeutic benefit.
Founded in 2007, Autonomic Technologies (ATI) is pioneering a miniaturized implantable neurostimulation device to provide rapid relief from the debilitating pain and suffering caused by severe headaches. The ATI neurostimulation system is being used in clinical studies for cluster headache and migraine.
Arcion Therapeutics applies breakthroughs in neuroscience to advance the treatment of chronic pain. The company focuses on innovative topical treatments to provide pain relief with convenient application and reduced systemic side effects. Arcion's product pipeline comprises multiple candidates to treat neuropathic pain.